Clinical Trial Update: Anifrolumab Malignancy and Serious Infections Study

View source ↗

Summary

AstraZeneca is recruiting for a clinical study of Anifrolumab in systemic lupus erythematosus, with monitoring for malignancy and serious infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Status: RECRUITING